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ABSTRACT 
Tuberculosis is an infectious disease whose global burden is fueled by HIV and several socio-economic factors, with worse 
outcomes in low and middle-income countries. This retrospective study was carried out to ascertain the prevalence of TB and 
HIV among TB suspected patients in a tuberculosis clinic in Benin, Nigeria between 2nd January, 2015 and 31st December, 2017.  
Clinical records of patients who had registered under the DOTS program, University of Benin Teaching Hospital, Benin City 
during the study period were deployed. This included information on demographic data, medical history, laboratory results and 
treatment access. Statistical analysis was carried out on available data. A total of 667 patients were enrolled during the study 
period. The highest TB prevalence was observed in 2015 (44.3%) while the lowest was in 2017 (32.1%). There was no significant 
difference in the prevalence of TB in relation to gender (p = 0.2760). The age group 21-30 yrs showed the highest TB prevalence 
(47.9%) while the least prevalence was observed for the age group ≤ 10 yrs (11.1%); this finding was statistically significant (p 
< 0.0001). There was no statistically significant relationship between year of TB infection and HIV sero-status (p >0.05), although 
8.4% of patients had HIV/TB co-infection. The prevalence of TB during this 3-year study review was 38.4%. Although a 
significant yearly decline in prevalence of TB was observed, the study draws attention on the need to address other socio-
economic factors that play key roles in fueling the disease in Nigeria. 
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INTRODUCTION 
 
Mycobacterium tuberculosis is the etiologic agent of 
tuberculosis, a leading cause of mortality and morbidity due 
to bacterial infections in the world and ranks second of all 
infectious agents due to microorganisms (Erah and Ojieabu, 
2009). Nigeria is one of the countries in sub-Saharan Africa 
where the disease is prevalent and has an unenviable place 
among the high burden countries in the world, where drug 
resistant TB and HIV/TB co-infection is prevalent (WHO, 
2017).  
 HIV/AIDS is another public health concern and is thought 
to have awakened the TB epidemic (Baltussen et al., 2005). 
Infected individuals are immune-compromised and 
susceptible to various microbial infections. Co-infection of 
TB and HIV has been considered to be a major obstacle for 
the global efforts in reaching the goals for the prevention of 
HIV and TB infections (Erah and Ojieabu, 2009). HIV 
infection is therefore an established risk factor predisposing to 
Mycobacterium tuberculosis infection and progression to 
active disease (Wood et al., 2011; Oladeinde et al., 2014). 
 Tuberculosis prevalence is linked with low socio-
economic living conditions as the incidence rate is 150-300 
per 100,000 in low income countries when compared to 10 per 
100,000 in high income countries (WHO, 2016; WHO, 2017). 
According to the WHO, the estimated incidence of TB in 
Nigeria is 322 per 100 000 population with only 15% of the 
total burden of the disease in the country being notified in 
2015 (WHO, 2016). The risk of developing tuberculosis is 
estimated to be between 16-27 times greater in people living 
with HIV than among those without HIV infection, while the 
likelihood of progressing to full blown AIDS increases by 100 
folds in HIV/TB co infected patients (WHO, 2017; Baltussen 
et al., 2005). 
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Several TB control programmes have been initiated in 
developing countries notably Nigeria, where the TB burden is 
high. They include the direct observed treatment short course 
(DOTS) program-instituted in the 1990’s by WHO, DOTS 
plus and Stop TB with the mandate of executing strategies 
aimed at reducing the global TB burden (WHO, 2016, Ibadin 
et al., 2018).  
 Previous studies in Benin city, Nigeria looked at various 
facets of TB disease among various groups; a six-year study 
on the prevalence of TB among HIV positive patients in a rural 
community in Edo state showed a prevalence of 32.8% 
(Oladeinde et al., 2014). Among smokers, a prevalence of 
48% was shown and among HIV patients attending 
dermatology clinic, a prevalence of 20% was shown 
(Ekrakene and Igeleke, 2010; Okoh and Omuemu, 2012). It is 
therefore imperative that a study evaluating the yearly 
prevalence of the disease among suspected TB patients 
attending DOTS clinic is carried out so as to access the impact 
of the program on the local burden of tuberculosis. It is against 
this background that this retrospective study was carried out 
to ascertain the prevalence of tuberculosis and HIV among 
patients attending DOTS clinic from 2015 to 2017. 
 
MATERIALS AND METHODS 
 
Study Population: The study was conducted at the University 
of Benin Teaching Hospital (UBTH) in Benin City, Nigeria. 
New cases of TB patients that attended National Tuberculosis 
and Leprosy Control Programme (NTBLCP), UBTH centre 
for treatment of TB between 2nd January, 2015 and 31st 
December 2017 constituted the sample population. 
 
Data Sources: The study was retrospective and clinical 
records and laboratory test results of patients who had 
registered under the DOTS program during the study period 
were deployed. Ethical approval was sought from the Ethical 
Committee of University of Benin Teaching Hospital. This 
was approved with Number: ADM/E 22/A/VOL. VII/1489. 
 
Sputum Processing: Triplicate sputum specimens were 
collected from patients in sterile wide-mouth containers and 
properly labeled. A loopful of sputum was thereafter spread 
on a clean glass slide uniformly in oval shape by smearing 
repeatedly in coil-like patterns, approximately 2-3 cm in size. 
The slide was air-dried and flame-fixed by passing through the 
flame carefully. The smear was then stained for presence of 
acid and alcohol fast bacilli using Ziehl-Nelseen staining as 
previously described (WHO, 2000). The tests were carried out 
by laboratory staff of tuberculosis laboratory, UBTH. 
 
HIV screening: All patients were subjected to HIV 
counseling after which venous blood was obtained from all 
participants. Five milliliters of blood sample was collected 
into properly labeled plain containers, samples were sent to 
the laboratory and HIV serological tests were carried out on 
the centrifuged blood samples. For the detection of HIV-1 and 
HIV-2 antibodies in the blood, Determine® HIV-1/2 Test 
cards (Inverness Medical, Japan), Unigold™ Kit (Trinity 
Biotec, Ireland) and HIV - 1/2 Stat- Pak® Assay (Chembio 
Diagnostic Systems, USA) according to the national algorithm 
(Mbachu et al., 2015). These methods are 
immunochromatographic and detect the presence of 
antibodies to HIV-1 and HIV-2 in human blood and are read 




The data obtained were analyzed with statistical tools namely 
chi square as appropriate using the statistical software 





A total of 667 patients were enrolled during the study period. 
Of this number, sputum samples of 256 (38.4%) patients were 
AAFB positive, with the highest prevalence observed in 2015 
(44.3%) and the lowest in 2017 (32.1%). In relation to yearly 
prevalence, the decline was statistically significant (p = 
0.0314). Three patients showed TB treatment failure during 
the study period with the year 2015 showing the highest 
prevalence (2.0%). The findings were not statistically 
significant (p = 0.4822) (Table 1). 
 
Table 1:  
Prevalence of tuberculosis in relation to various years 
Year No of patients 
screened 







2015 221 98 (44.3) 2 (2.0) 
2016 231 89 (38.1) 1 (1.1) 
2017 215 69 (32.1) 0 
Total 667 256 (38.4) 3 (1.2) 
†p = 0.0314; *p = 0.4822 
 
 There was no significant difference in the prevalence of 
TB in relation to gender although females showed higher 
prevalence (p = 0.2760). In relation to age, the highest 
prevalence was observed for the age group 21-30 years, while 
the least prevalence was observed for the age group ≤ 10 years. 
The finding was statistically significant (p < 0.0001) (Table 
2). 
 
Table 2:  
Prevalence of tuberculosis in relation to age and gender 
  No of 
Patients 
screened 




Gender Male 350 127 (36.3)  
0.2760 Female 317 129 (40.7) 





11-20 60 27 (45.0) 
21-30 146 70 (47.9) 
31-40 167 79 (47.3) 
41-50 104 36 (34.6) 
51-60 76 25 (32.9) 




Table 3:  
Prevalence of tuberculosis in relation to HIV status from 2015-2017 
 
Year 
HIV sero-positive patients HIV sero-negative patients  
Number tested No infected with TB Number tested No infected with TB p 
2015 67 25 (37.3) 154  72 (46.8) 0.2492 
2016 57 19 (33.3) 174 70 (40.2) 0.4403 
2017 49 12 (24.5) 166 56 (33.7) 0.2946 
Total 173 56 (32.4) 494 198 (40.1) 0.0879 
 
 Of 173 patients that were sero-positive for HIV during the 
study period, 56 (32.4%) were AAFB positive. Also, of the 
494 patients that were HIV sero-negative, 198 (40.1%) were 
AAFB positive. There was no statistically significant 
relationship between year of TB infection and HIV sero-status 





In the current study, the prevalence of tuberculosis among TB 
suspected patients was 38.4% with a yearly decline in 
prevalence that was statistically significant. This finding 
underscores the relative success in TB intervention schemes 
aimed at reducing the burden of the disease. The strategy is 
summed up in the Direct observation treatment short course 
(DOTS) program which has a five pronged approach that 
includes; political commitment from stakeholders, case 
detection through quality-assured bacteriology, standardized 
treatment with supervision and patient support, effective drug 
supply and management system, monitoring and impact 
measurement (WHO, 2013). It must however be noted that 
Nigeria is still among the high burden countries and remains a 
flashpoint for tuberculosis studies as several precipitating 
factors abound namely HIV burden, malnutrition, 
overcrowding and low-level development of health 
infrastructures (Erah and Ojieabu, 2009). Also, treatment 
failure was observed in 1.2% of AAFB positive patients. The 
commonest cause of treatment failure is drug resistance and 
multi-drug resistant TB (MDR-TB) is caused by strains of M. 
tuberculosis that is resistant to both isoniazid and rifampicin 
(Kaur et al., 2013). These patients require prolonged and 
expensive treatment using second-line medications that are 
less effective and more toxic (WHO, 2016). Definitive and 
timely detection of MDR-TB can be done using the Gene-
Xpert diagnostic platform from a single specimen in 
comparison to culture which is time consuming, laborious and 
requires technical experience. This study therefore 
emphasizes the need for most DOTS TB testing centres to 
have the Gene-Xpert diagnostic platform so as to facilitate 
detection, tracking of patients and monitoring of therapy. 
 Although the global male:female (M:F) ratio for TB 
notification is 1.7 (WHO, 2017), gender did not play a 
significant contributory role to the local TB burden in this 
study. This observation is in accordance with several studies 
though females had a slightly higher prevalence in this study 
(40.7%) (Okonkwo et al., 2015; Oladeinde et al., 2014). 
However, age significantly affected TB prevalence as patients 
in the age group 21-30 yrs showed the highest prevalence 
while patients less than 10 yrs had the lowest prevalence. This 
age group constitutes the most active and mobile group and 
are more prone to predisposing factors for TB such as drug 
abuse, alcoholism, smoking, and poor living conditions 
occasioned by unemployment and poverty (Kochi, 1991). In 
previous studies in Okada and Benin, Edo state respectively, 
patients in the age group 21-30 had the highest prevalence 
(Egbagbe et al., 2011; Oladeinde et al., 2014).  
 HIV is thought to have reawakened the tuberculosis 
scourge and patients who are HIV positive and infected with 
TB have been previously shown to be 17 times more likely to 
develop active TB than people not infected with HIV (Wood 
et al., 2011). In this study, there was no statistically significant 
relationship between TB infection and HIV sero-status. This 
finding does not downplay the role of HIV in the resurgence 
of TB, rather, it draws attention to other contributory factors 
to the burden of TB in our locality. Prevailing social factors 
such as poor socio-economic status of the people, 
malnutrition, crowded living conditions due to urban drive and 
high population growth rate are rife in Benin and most other 
cities in Nigeria (Oladeinde et al., 2014). These factors have 
been strongly linked with the global burden of tuberculosis in 
high burden countries and must be tackled alongside 
HIV/AIDS so as to mitigate the negative impact on the health 
of the teeming population.  
 The rate of HIV/TB co-infection among patients attending 
DOTS clinic in this study was 8.4%. This value represents a 
significant rise from previous studies in South-East Nigeria 
and Punjab, India which reported 6.4% and 1.32% 
respectively (Okonkwo et al., 2015; Kaur et al., 2013). It is 
however lower than a previous study in a facility (Central 
Hospital) in Benin which reported 20% and another in Lagos 
which reported 18.4% prevalence (Okoh and Omuemu, 2012; 
Onubogu et al., 2010). In Okoh and Omuemu’s study in Benin 
however, the study population comprised HIV positive 
subjects.  The differences in prevalence in the other cited 
studies may be due to differences in the prevailing socio-
economic factors earlier highlighted that fuel the disease 
entity.  
 In conclusion, the prevalence of TB during this 3-year 
study review was 38.4%. Age was a risk factor for TB with 
the age group 21-30 yrs showing the highest prevalence. Co-
infection of TB/HIV was 8.4%. Although a significant decline 
in prevalence of TB was observed, the study draws attention 
on the need to address other socio-economic factors that play 
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